Ai Powered Cancer Vaccines

AI-Powered Personalized Cancer Vaccines

Why invest in Ai-Powered Cancer Vaccines?

AI-first engine (NeoGenAI)

Proprietary models claim >90% neoantigen prediction accuracy, enabling vaccine design within ~2 weeks (big time and cost advantage vs typical workflows).

Meaningful traction & credits

£400K equity funding to date, strategic computing & reagent credits (Google, NVIDIA, Illumina) reducing cash burn and de-risking platform scale.

Preclinical evidence

Vaccine candidates have shown efficacy in mouse tumor models (lung, skin, colon).

AI-Powered Personalized Cancer Vaccines
Investing in a scalable, rapid, and personalized future of cancer treatment.
Fundraise: £15M target to reach IND readiness and execute Phase 1 clinical trials.

Request Project Prospectus

Fund Investment Highlights

142% revenue growth (2026–2030 trajectory) and 68% gross margin, with EBITDA $84M by 2030
Payback / Breakeven (rough): under the base cases the return multiples imply payback well within the 5-year horizon .
Dilution note: these calculations are pre-dilution . Real investor returns depend strongly on round structure, warranting, liquidation preference, and follow-on rounds.
Royalties / recurring revenue: SaaS licensing, royalties, and clinical application revenue streams.

Speed & Cost Efficiency via AI-Driven Neoantigen Discovery

NeoGenAI platform is designed to predict neoantigens with high accuracy, dramatically shortening the vaccine design timeline (from months to ~2 weeks in some cases)

Strong De-risking Through Traction & Strategic Partnerships

The company already has significant in-kind credits (e.g. computing, reagents) from major platforms like Google, NVIDIA, and Illumina, which reduce capital burden and cash burn.

Large Addressable Market + Clear Exit Pathways

The total addressable market for personalized cancer vaccines and neoantigen therapies is massive, with growing demand globally — and even more so in oncology markets where personalized and targeted treatments are increasingly prioritized.

Positive Financial Upside & Scalability

Projections show strong revenue growth, good gross margins, and profitability by the target exit horizon, enabling high return multiples.

Investing in to this project offers exposure to a high-growth oncology market through an AI-powered platform that can dramatically shorten cancer vaccine development timelines while reducing costs. With strong preclinical results, strategic partnerships, and a clear path to commercialization, the project is positioned to deliver outsized returns alongside meaningful healthcare impact.